Jessica Notohardjo

4PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersInnate immunityMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 07, 2026
Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma.

|Jul 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia

|Jul 01, 2024
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients.

Marise R Heerma van Voss, Jessica Notohardjo, Joyce van Dodewaard-de Jong

|Jul 20, 2022
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T<sub>reg</sub> reduction and effector T cell activation.

Kim M van Pul, Jessica C L Notohardjo, Marieke F Fransen

Pageof 1

Frequent Collaborators

2 joint publications

Alfonsus J M van den Eertwegh

2 joint publications

Tanja D de Gruijl

1 joint publications

Kim M van Pul

1 joint publications

Marieke F Fransen